ArticleMedicine2026
Association between serum dehydroepiandrosterone sulfate and type 2 diabetes in US adults with adiposity as a mediator.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dehydroepiandrosterone sulfate (DHEAS) is the most abundant adrenal androgen in circulation, yet its relationship with type 2 diabetes mellitus (T2DM) and the mediating role of adiposity remain unclear. We analyzed data from 4707 US adults (584 with T2DM, 4123 without diabetes) in the National Health and Nutrition Examination Survey 2021-2023. Serum DHEAS was quantified by isotope dilution LC-MS/MS. Survey-weighted logistic regression assessed the association between DHEAS and T2DM, adjusting sequentially for demographics, sex hormones, and measures of adiposity (body mass index, waist circumference, waist-to-hip ratio, and body roundness index). Restricted cubic splines tested for nonlinear relationships. Mediation analysis quantified the proportion of the DHEAS-T2DM association explained by adiposity. Median serum DHEAS was significantly lower in T2DM than in nondiabetic participants (1.28 vs 2.65 µmol/L; P < .001). Higher DHEAS was associated with reduced odds of T2DM after adjustment for demographics, hormones, and body mass index (per 1 µmol/L: odds ratio 0.87, 95% confidence interval 0.78-0.97). Individuals in the highest DHEAS quartile had lower T2DM odds compared with the lowest quartile (odds ratio 0.44, 95% confidence interval 0.20-0.99). Sex-stratified analysis showed a robust inverse association in men, but not in women. Restricted cubic splines analysis revealed a nonlinear, threshold effect, notably in men. Mediation analysis indicated that adiposity explained 14.4% to 21.8% of the inverse association. In a nationally representative US sample, higher serum DHEAS was independently associated with lower odds of T2DM, particularly among men, with partial mediation by adiposity, highlighting both adiposity-dependent and independent pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.